University of Pennsylvania

Novartis Ag

Fondazione Irccs Istituto Nazionale Dei Tumori

University of Texas System

Daniel J Powell

Carl H June

Andreas Loew

Michael C Milone

Yangbing Zhao

Nathalie Scholler

Katarzyna Urbanska

Bruce L Levine

Aizhi Zhao

Jan J Melenhorst

Felipe Bedoya

Denarda Dangaj

Saba Ghassemi

Zoe Zheng

George Coukos

Mariangela Figini

Silvana Canevari

Saar Gill

Marco Ruella

Avery D Posey

Nicola Mason

Omkar U Kawalekar

Mohammed Kazim Panjwani

Jenessa Smith

Andrew Tsourkas

Laurence Jn Cooper

Colleen M O'Connor

Caitlin Stashwick

Nathan Amar Singh

David M Barrett

David Maxwell Barrett

The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.

Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein

The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.

Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.

Use of trans-signaling approach in chimeric antigen receptors

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Methods for improving the efficacy and expansion of immune cells

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

Human alpha-folate receptor chimeric antigen receptor

The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens

Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells

The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor that comprises a protein or peptide tag, such as a SpyCatcher or a SpyTag moiety, bound to an extracellular hinge region, a transmembrane domain, and an intracellular domain for T cell activation.

SpyCatcher and SpyTag: universal immune receptors for T cells

Fully-human t-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having &#x3b1;-folate receptor (FR&#x3b1;) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Compositions and methods for treating cancer

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

Car-expressing cells against multiple tumor antigens and uses thereof

Growing community of inventors

Bala Cynwyd, PA, United States of America

Daniel J Powell